‘Biothrax’ Archive

Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax July 7, 2011 No Comments

ROCKVILLE, Md., — Emergent BioSolutions Inc. (NYSE:EBS) announced on June 23rdthat the Singapore Health Sciences Authority (HSA) has approved Emergent’s product license application for the marketing and sale of BioThrax(R) (Anthrax Vaccine Adsorbed) in Singapore. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) to protect against anthrax infection.
“Emergent is [...]

Filed under Biothrax, Chief executive officer, Emergent BioSolutions, Halth Care, U.S. Food and Drug Administration, fuad el-hibri
Tags: , , , , ,

Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule June 7, 2011 No Comments

ROCKVILLE, Md., May 31, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that eight lots of BioThrax(R) (Anthrax Vaccine Adsorbed) have received regulatory release for delivery to the U.S. government under the company’s contract (200-2009-30162) originally written to supply 14.5 million doses of BioThrax to the Strategic National Stockpile. This marks the largest [...]

Filed under Biothrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, U.S. Food and Drug Administration, fuad el-hibri
Tags: , , , , ,

Emergent BioSolutions Reports Financial Results for First Quarter 2011 May 12, 2011 No Comments

ROCKVILLE, Md., May 05, 2011 (BUSINESS WIRE) — Emergent BioSolutionsInc. (NYSE: EBS) announced  its financial results for the first quarter ended March 31, 2011.
For 1Q 2011, total revenues were $18.5 million as compared to $46.8 million in 2010. In addition, for 1Q 2011 the company recorded a net loss of $21.4 million, or $0.61 per [...]

Filed under BioDefense, Biothrax, Business, Chief executive officer, Chief financial officer, Revenue
Tags: , , , , ,